Inovio Pharmaceuticals Inc (INO)

[thomaswalsh]

The following is my OPINION only....

As I mentioned in the previous months leading up to data release, INO needed the Hep C data to be EPIC to create visibility with synthetic DNA technology. INO's only revenue generating asset is Electroporation. At this point, they will most likely DISCONTINUE HEP C clinical trial, and proceed with other pipelines. Problem is, they just diluted, stock dipped 10-20%, now that cash pile will be depleted to proceed with R&D. In a nutshell, this bio will most likely be one of the 99% that fail. If I was Kim, I would partner in order to create financial backing for R&D. INO is running out of financing options IMO.

With that said, as a prof in the medical field, I am intrigued with their technology. Emotionally, I want INO to be groundbreaking not just for my trading accounts, but for the future of medicine etc.

Bio is INCREDIBLY DIFFICULT AND CUT THROAT, just remember this going forward folks. Have a good day and good luck with your trades.